Just for fun, I queried Chat GPT to write a CRISPR sequence that could treat Kennedy’s Disease. Here’s its response:

Designing a CRISPR sequence for treating spinal bulbar muscular atrophy (SBMA), also known as Kennedy's disease, would involve targeting the causative gene, the androgen receptor (AR) gene. SBMA is an X-linked recessive disorder caused by a CAG trinucleotide repeat expansion in the AR gene, leading to abnormal protein aggregation and motor neuron degeneration.

Here is an example CRISPR sequence that could be used for SBMA treatment:

5'-GAACTGAGCGTCTTCCACAGGG-3' (targeting the AR gene)

This sequence targets the region around the CAG repeat expansion in the AR gene, with the goal of cutting the expanded repeat region and inducing DNA repair processes that will remove the expanded repeats from the genome. This could potentially reduce the abnormal protein aggregation and motor neuron degeneration associated with SBMA.

It's worth noting that designing a CRISPR sequence for SBMA treatment is a complex process that requires careful consideration of the potential off-target effects and delivery methods. This sequence is just an example and would need to be thoroughly tested in preclinical and clinical studies before it could be used as a treatment for SBMA.

——

Who knows if this could work, but my point is AI may be able to accelerate research for not only KD but hundreds of other chronic diseases. Exciting stuff!

Want to take the next small step or giant leap? It's getting much cheaper and easier.
https://www.the-odin.com/

Interesting to see a 2023 AI / ChatGPT advise
I remember how useless was early AI, while now AI is augmenting my daily work, actually AI is better than me in my work

Anyhow, I copy the reply to the last available ChatGPT and he provide a much longer explanation now ... including corrections

Here is the start of it :

Yes. The 2023 proposal can be improved considerably, particularly in terms of scientific accuracy, therapeutic strategy, and the possibility of turning the idea into a serious research project.

The first thing I would change is the approach: I would not start by designing a CRISPR guide RNA. I would start by designing a therapeutic strategy for selectively correcting the expanded androgen receptor (AR) gene.

There is an important distinction between having a CRISPR sequence that appears to target the AR gene and having a sequence that can safely and effectively treat spinal and bulbar muscular atrophy (SBMA).
1. What is wrong with the original proposal?
The proposed sequence: